Abstract:Serous endometrial and ovarian cancers represent significant morbidity and mortality for gynecologic cancers due to the high rate of resistance to chemotherapy and recurrence after treatment. Among the many reasons for poor outcomes is a lack of preclinical models that reflect the complex heterogeneity across patients. Our objective was to create patient-derived organoid (PDO) models of serous endometrial and ovarian cancer and examine how genomic profiles evolve in response to standard therapy. This study was performed in four PDO models of serous gynecologic cancer, including serous endometrial, high grade and low grade serous ovarian, and high grade serous fallopian tube. We first compared genomic alterations in the primary tumors and PDOs using a 484-gene NGS panel (NovoPM 2.0, Novogene). A large overlap in single nucleotide variants (SNVs), copy number variations (CNVs) and indels was observed between primary tumor tissue and the corresponding PDO model. For example, there was an average of 175 shared SNVs between each primary tumor and PDO model and <20 unique variants in the PDO that were not present in primary tumor specimen. For the patient with serous fallopian tube cancer, we were further able to generate PDO models from tumor tissue acquired from three different sites: ovary, omentum, and ascites fluid. We found that 217 SNVs were shared among the PDOs from the three sites, with only 2-11 variants unique to each location. Interestingly, eight unique CNVs were detected in the ovary and ascites PDOs but not in the metastatic (omentum) PDO. We next exposed each PDO to a short 3-day pulse of carboplatin+paclitaxel to create chemoexposed models. The rationale for this duration of exposure is that clinical response in patients has been shown to correlate with drug response at 72 hrs in PDO models of ovarian cancer. As expected, all chemoexposed PDOs were more resistant to chemotherapy as compared to treatment-naïve counterparts. Genomic analysis of the treatment-naïve vs. chemoexposed PDOs revealed acquisition of new variants, such as a p53 mutation in the serous endometrial model after the pulse of chemotherapy. Finally, we compared drug sensitivity of the treatment-naïve vs. chemoexposed PDOs to agents used in the adjuvant and recurrent settings. The chemoexposed models yielded different drug profiles, with some showing increased sensitivity and others increased resistance. Taken together, these data substantiate that PDO models retain tumor heterogeneity, exhibited by the different genomic profiles and varying chemosensitivity. In addition, PDO models can be used to model the genomic and drug response profiles that arise in response to chemotherapy. Citation Format: Andreea Newtson, Emily Symons, Paige Malmrose, Eric Devor, Samantha Parks, Craig Rush, Jessica Andrew-Udoh, Haley Losh, Jay Gertz, Kristina Thiel, Kimberly Leslie. Use of patient-derived organoids to model tumor evolution in response to chemotherapy [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl) nr B032.

Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer

Patient-Derived Organoids (Pdo) As The Potential Model To Predict Treatment Outcome Of Rectal Cancer Patients Underwent Neo-Adjuvant Chemoradiotherapy

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Colorectal Cancer Tissue-Originated Spheroids Reveal Tumor Intrinsic Signaling Pathways and Mimic Patient Clinical Chemotherapeutic Response As a Rapid and Valid Model

Accuracy Of Using A Patient-Derived Tumor Organoid Culture Model To Predict The Response To Chemotherapy Regimens In Stage Iv Colorectal Cancer A Blinded Study

IDDF2022-ABS-0105 Patient-derived Organoids Can Predict Chemotherapy Response of Gastric Cancers and Analysis of Its Molecular Characteristics

Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

Abstract B032: Use of patient-derived organoids to model tumor evolution in response to chemotherapy

The Establishment of Patient-Derived Organoid Models and Drug Response of Resectable Non-Small Cell Lung Cancer

Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer

389PThe establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients with Stage IV Colorectal Cancer after Surgery

IDDF2022-ABS-0194 Patient-derived Organoids Predict Chemotherapy Response in Biliary Tract Cancer

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy

Organoid Models Derived from Primary Tumors and Patient-Derive Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer Patients

Author Response for "use of Patient‐derived Tumor Organoid Platform to Predict the Benefit of Postoperative Adjuvant Chemotherapy for Poor Responders to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer"